With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.129779-30-2,(3R,5S)-rel-tert-Butyl 3,5-dimethylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
To a solution of 5-fhioroquinoline-8-carbonitrile (compound lc, 1.4 g, 8.1 mmol) in DMSO (20 mL) was added (3/^,5.S’)-3,5-dimethylpiperazine- 1 -carboxylate (compound Id) (1.7 g, 1.7 mmol) and DIEA (878 mg, 6.8 mmol). The reaction mixture was stirred at 120 C for 3 hrs, then cooled to room temperature, diluted with water (100 mL), and extracted with EA (150 mL) twice. The combined organic layer was washed with brine, dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 80 g, 10% to 50% EtOAc in PE). The purified intermediate was dissolved in DCM (20 mL) and TFA (5 mL) was added. The reaction mixture was stirred at room temperature for 3 hrs, then concentrated to afford a crude compound 3b (1.6 g, 75% yield). MS: calc?d 266 [(M+H)+], measured 266 [(M+H)+], 129779-30-2
As the paragraph descriping shows that 129779-30-2 is playing an increasingly important role.
Reference£º
Patent; F. HOFFMANN-LA ROCHE AG; HOFFMANN-LA ROCHE INC.; DEY, Fabian; QIU, Zongxing; ZHU, Wei; ZOU, Ge; (55 pag.)WO2020/20800; (2020); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics